Clinical Study of Recombinant Mycobacterium Tuberculosis Fusion Protein for 65-year-olds and Above
Condition: Latent Tuberculosis Infection Interventions: Biological: Recombinant Mycobacterium Tuberculosis Fusion Protein; Biological: Purified Protein Derivative of Tuberculin Sponsors: Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.; Shenzhen Third People's Hospital; Wuhan Institute for Tuberculosis Control Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials